58 related articles for article (PubMed ID: 30820933)
1. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.
Kröger N; Eikema DJ; Köster L; Beelen D; de Wreede LC; Finke J; Koenecke C; Niederwieser D; Bornhäuser M; Schoenland S; Potter V; Wolschke C; Maertens J; Theobald M; Kobbe G; Itälä-Remes M; Wulf G; Kahls P; Forcade E; Greinix H; Masszi T; Yakoub-Agha I; Chalandon Y; Robin M;
Br J Haematol; 2019 May; 185(4):725-732. PubMed ID: 30820933
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Zhang T; Zhang Y; Zhou M; Zhang Z; Bao X; Wen L; Feng Y; Li X; Zhai M; Liu X; Zeng Z; Wu X; Chen S
Br J Haematol; 2024 Apr; 204(4):1402-1413. PubMed ID: 38327115
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
4. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Tazoe K; Harada N; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Hirose A; Nakamae M; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H
Ann Hematol; 2024 Jun; 103(6):2059-2072. PubMed ID: 38662207
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT.
Rovó A; Gras L; Piepenbroek B; Kröger N; Reinhardt HC; Radujkovic A; Blaise D; Kobbe G; Niityvuopio R; Platzbecker U; Sockel K; Hunault-Berger M; Cornelissen JJ; Forcade E; Bourhis JH; Chalandon Y; Kinsella F; Nguyen-Quoc S; Maertens J; Elmaagacli A; Mordini N; Hayden P; Raj K; Drozd-Sokolowska J; de Wreede LC; McLornan DP; Robin M; Yakoub-Agha I; Onida F
Am J Hematol; 2024 Feb; 99(2):203-215. PubMed ID: 38009469
[TBL] [Abstract][Full Text] [Related]
6. Tripartite prehabilitation of patients with acute myeloid leukaemia and high-risk myelodysplastic syndromes during intensive chemotherapy before allogeneic haematopoietic stem cell transplantation (COHABILIT): protocol for an innovating prospective multicentre study.
Saillard C; Cuvelier S; Villaron-Goetgheluck C; Boher JM; Almeida-Lopez L; Le Corroller AG; Denis P; Rivieccio C; Calvin S; Vey N; Bannier-Braticevic C
BMJ Open; 2024 Mar; 14(3):e076321. PubMed ID: 38553062
[TBL] [Abstract][Full Text] [Related]
7. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Jachiet V; Moulis G; Hadjadj J; Seguier J; Laribi K; Schleinitz N; Vey N; Sacre K; Godeau B; Beyne-Rauzy O; Bouvet R; Broner J; Brun N; Comont T; Gaudin C; Lambotte O; Le Clech L; Peterlin P; Roy-Peaud F; Salvado C; Versini M; Isnard F; Kahn JE; Gobert D; Adès L; Fenaux P; Fain O; Mekinian A
Haematologica; 2021 May; 106(5):1414-1422. PubMed ID: 33626866
[TBL] [Abstract][Full Text] [Related]
8. Atypical chronic myeloid leukaemia: A case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group.
Drozd-Sokołowska J; Mądry K; Waszczuk-Gajda A; Biecek P; Szwedyk P; Budziszewska K; Raźny M; Dutka M; Obara A; Wasilewska E; Lewandowski K; Piekarska A; Bober G; Krzemień H; Stella-Hołowiecka B; Kapelko-Słowik K; Sawicki W; Paszkowska-Kowalewska M; Machowicz R; Dwilewicz-Trojaczek J
Hematol Oncol; 2018 Mar; ():. PubMed ID: 29512182
[TBL] [Abstract][Full Text] [Related]
9. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia].
Zhang XH; Zhou JY
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):18-21. PubMed ID: 38527833
[TBL] [Abstract][Full Text] [Related]
10. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
de Castro FA; Mehdipour P; Chakravarthy A; Ettayebi I; Loo Yau H; Medina TS; Marhon SA; de Almeida FC; Bianco TM; Arruda AGF; Devlin R; de Figueiredo-Pontes LL; Chahud F; da Costa Cacemiro M; Minden MD; Gupta V; De Carvalho DD
Br J Haematol; 2024 Jan; 204(1):206-220. PubMed ID: 37726227
[TBL] [Abstract][Full Text] [Related]
11. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
Wang YH; Yao CY; Lin CC; Gurashi K; Amaral FMR; Bossenbroek H; Jerez A; Somervaille TCP; Binder M; Patnaik MM; Hou HA; Chou WC; Batta K; Wiseman DH; Tien HF
Br J Haematol; 2023 Apr; 201(2):302-307. PubMed ID: 36746431
[TBL] [Abstract][Full Text] [Related]
12. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study.
Kurosawa S; Shimomura Y; Ishiyama K; Fuse K; Shimazu Y; Doki N; Uchida N; Tanaka M; Takahashi S; Sakurai M; Kobayashi H; Katayama Y; Takada S; Ozeki K; Nakamae H; Ishimaru F; Kanda Y; Ichinohe T; Atsuta Y; Itonaga H
Bone Marrow Transplant; 2024 Feb; ():. PubMed ID: 38331981
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression.
Auerbach S; Puka B; Golla U; Chachoua I
Life (Basel); 2024 Feb; 14(3):. PubMed ID: 38541635
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
Bauer M; Jäkel N; Wilfer A; Haak A; Eszlinger M; Kelemen K; Haemmerle M; Al-Ali HK; Seliger B; Wickenhauser C
Oncoimmunology; 2024; 13(1):2323212. PubMed ID: 38481730
[TBL] [Abstract][Full Text] [Related]
15. Anti-GABA
Rusche T; Yaldizli Ö; Galbusera R; Mutke M; Halter JP; Lieb J; Matteazzi F; Stelmes A; Bittner J; Grzonka P; Frank N; Cordier D; Hench J; Frank S; Hirsch HH; Fischer U; Kuhle J; Sutter R; Rüegg S; Fisch U
Lancet; 2024 Feb; 403(10425):469-470. PubMed ID: 38309783
[No Abstract] [Full Text] [Related]
16. Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
Mahdi D; O'Nions J; Raj K; Baker R; Jarratt R; Williams D; Burt R
Br J Haematol; 2023 Dec; 203(5):e114-e116. PubMed ID: 37743541
[No Abstract] [Full Text] [Related]
17. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.
Mughal TI; Pemmaraju N; Bejar R; Gale RP; Bose P; Kiladjian JJ; Prchal J; Royston D; Pollyea D; Valent P; Brümmendorf TH; Skorski T; Patnaik M; Santini V; Fenaux P; Kucine N; Verstovsek S; Mesa R; Barbui T; Saglio G; Van Etten RA
Hematol Oncol; 2022 Oct; 40(4):491-504. PubMed ID: 35368098
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.
Koo RM; Wong E; Davis JE; Perera T; Lim A; Koldej RM; Ritchie DS
Bone Marrow Transplant; 2024 Mar; ():. PubMed ID: 38538726
[No Abstract] [Full Text] [Related]
19. Acute onset severe hypophosphataemia in transformed acute myeloid leukaemia: an unusual biochemical presentation.
Cashion C; Bonnitcha P; Stevenson W
J Clin Pathol; 2023 Nov; ():. PubMed ID: 37985139
[No Abstract] [Full Text] [Related]
20. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
